

+

APR 15 2002

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0051-0051  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	10/067,996
Filing Date	February 8, 2002
First Named Inventor	Allen T. Hopper
Group Art Unit	Unassgined
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-2

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

[illegible]


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A15	DE	2 405 895			08-29-1974		
	A16	DE	42 30 755			03-17-1994		
	A17	DE	197 02 785			07-30-1998		
	A18	DE	199 35 209			02-08-2001		
	A19	JP	62-10085			01-19-1987		
	A20	JP	10-72415			03-17-1998		
	A21	JP	11-180982			07-06-1999		
	A22	JP	11-189577			07-13-1999		
	A23	JP	2000-72773			03-07-2000		
	A24	WIPO	WO 93/25517			12-23-1993		
	A25	WIPO	WO 94/14742			07-07-1994		
	A26	WIPO	WO 98/58901			12-30-1998		
	A27	WIPO	WO99/24432			05-20-1999		
	A28	WIPO	WO 99/29694			06-17-1999		
	A29	WIPO	WO 01/87281			11-22-2001		

Date  
Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/067,996
Filing Date	February 8, 2002
First Named Inventor	Allen T. Hopper
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-2

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A30	THOMAS C. MCKENZIE et al., "The Gornberg-Bachmann Reaction of Purines", <u>J. Heterocyclic Chem.</u> , May-Jun 1987, pp. 859-861, Vol. 24	
	A31	VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2', 3'- Dideoxyadenosine," <u>J. Am. Chem. Soc.</u> , 1989, pp. 8502-8504, Vol. 111	
	A32	VASU NAIR et al., "Synthesis Of Congeners Of Adenosine Resistant To Deamination By Adenosine Deaminase," <u>J. Chem. Soc Comm.</u> , 1989, pp. 878-879	
	A33	JAMES L. KELLEY et al., "Synthesis and Structure- Activity Relationships of 2-Substituted-6- (dimethylamino)- 9- (4-methylbenzyl)-9H-purines with Antirhinovirus Activity," <u>J. Med. Chem.</u> , 1989, pp. 218-224, Vol. 32	
	A34	JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," <u>Eur. J. Med. Chem.</u> , 1990, pp. 131-135, Vol. 25	
	A35	ROGER J. SCHILLING et al., "A High-Throughput Assay For Cyclic Nucleotide Phosphodiesterases," <u>Analytical Biochemistry</u> , 1994, pp.154-158, Vol. 215	
	A36	DONALD V. DANIELS et al., "A Semiautomated Method for the Assay of Cyclic Adenosine 5'-Monophosphate Phosphodiesterase," <u>Analytical Biochemistry</u> , 1996, pp. 367-369, Vol. 236	
	A37	JEAN-JACQUES BOURGUIGNON et al., "9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors," <u>J. Med. Chem.</u> , 1997, pp. 1768-1770, Vol. 40	
	A38	JAMES L. KELLEY et al., "6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents," <u>J. Med. Chem.</u> , 1997, pp. 3207-3216, Vol. 40	
	A39	HIROYUKI SAWANISHI et al., "Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines", <u>J. Med. Chem.</u> , 1997, pp. 3248-3253, Vol. 40	
	A40	J.E. SOUNNES et al., "Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP Phosphodiesterases", <u>Cell Signal</u> , 1997, pp. 227-236. Vol. 9, No. 3-4	
	A41	MARY ELIZABETH BACH et al., "Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long term potentiation <i>in vitro</i> and are attenuated by drugs that enhance the cAMP signaling pathway", <u>Proc. Natl. Acad. Sci. USA</u> , April 1999, pp.5280-5285, Vol. 96	
	A42	ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine," <u>The Journal Of Pharmacology And Experimental Therapeutics</u> , 2000, pp. 647-653, Vol 292, No.2	

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/ (12/31/2007)